Loading…
← CockpitCompetitor Analysis › 048410.KS Hyundai Bioscience Co. Ltd.Open in the cockpit ↗

Hyundai Bioscience Co. Ltd.048410.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major
Momentum neutral 40
Mkt cap
$424M
US dollars, full cap
Free float
89%
of shares outstanding
$/day
$4.21M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-24.8 pp
WACC 8.0%
Hurdle
n/a
no reverse DCF
Close · KRW₩6,050
1D+1.3%
1W+3.6%
1M-9.6%
3M-20.0%
6M-50.2%
YTD+21.9%
1Y+16.8%
ATR %8.1%
52w lowhigh71.9% off high

What Hyundai Bioscience does

Employees: 67

Hyundai Bioscience at a glance

Size Hyundai Bioscience (048410.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $424M, the 384th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩6,050 on 18 Nov 2026.

Performance Over six months the shares fell 50.2%, against -20.8% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 78.0% over the last twelve months (peer median +3.4%); the operating margin is -580.2% (peer median -3.3%).

Valuation It trades at 164.0× enterprise value to sales against a peer median of 3.0× (2nd most expensive of 19).

Capital Return on invested capital runs 24.8 points below its cost of capital (8.0% WACC).

Relative performance

507510012521 May 202621 Aug 202618 Nov 2026Peer median 82048410.KS 54
Six months, rebased to 100: Hyundai Bioscience against the median of its 20 peers (local-currency closes).

Hyundai Bioscience financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩3.32B₩3.52B₩15.1B₩9.48B₩7.85B
Revenue growth—-77%+59%+21%—
Gross profit-₩1.00B-₩1.03B₩11.2B₩3.92B₩1.95B
EBITDA-₩17.8B-₩16.9B₩1.47B-₩8.37B-₩24.5B
Net income-₩26.5B-₩22.1B-₩6.93B-₩14.5B-₩15.8B
Free cash flow-₩17.7B-₩18.6B₩1.65B-₩6.84B-₩17.6B
Capital expenditure₩1.01B₩20.2B₩2.17B₩588M₩1.54B
Total debt₩22.8B₩17.8B₩26.6B₩5.55B₩6.25B

Quarterly statements and history in the cockpit →

Hyundai Bioscience competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%4114601089001060OVIDZOTATVGN600613603139002728002923PHAT6881176050776881367871000518000788002900RZLTCTMX048410.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Hyundai Bioscience is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%+6,000%0×100×200×4114601089OVID7871000518048410.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hyundai Bioscience is the large dot.

Hyundai Bioscience competitors and peer comparison

How Hyundai Bioscience compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hyundai Bioscience against its 20 peers (data as of 18 Nov 2026)
Measure048410.KSPeer medianRank in peer set
1-month return-9.6%-13.0%7th highest of 21
6-month return-50.2%-20.8%2nd lowest of 21
Distance from 52-week high-71.9%-47.7%3rd lowest of 21
Revenue growth (TTM)+78.0%+3.4%3rd highest of 19
Operating margin-580.2%-3.3%3rd lowest of 19
EV / Sales164.0×3.0×2nd most expensive of 19
ROIC minus cost of capital-24.8 pp-7.0 pp4th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Hyundai Bioscience 048410.KSSouth Korea$424M-50%+78%-580%164.0×n/an/a
Synmosa Biopharma 4114.TWOTaiwan$423M-1%+21%10%2.2×5.4%+15.3%
Beijing Foyou Pharma 601089.SSChina$423M-27%+5%10%0.2×n/an/a
JW Pharmaceutical 001060.KSSouth Korea$423M-26%+9%13%0.7×-15.4%+7.2%
Ovid Therapeutics OVIDUnited States$427M-5%-78%-4,700%208.3×n/an/a
Zota Health Care ZOTA.NSIndia$427M+9%+69%-16%6.2×n/an/a
Tevogen TVGNUnited States$422M-38%n/an/an/an/an/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SSChina$427M+4%-4%3%1.2×10.6%+1.4%
Shaanxi Kanghui Pharmaceutical Co 603139.SSChina$421M-31%+1%-39%7.1×n/an/a
Teyi Pharmaceutical 002728.SZChina$419M-12%-7%7%3.2×24.4%+8.0%
Zhuhai Rundu Pharmaceutical 002923.SZChina$430M-30%+14%5%2.2×1.4%-1.3%
Phathom Pharmaceuticals PHATUnited States$431M-55%+87%-9%2.9×n/an/a
Cheng Du Sheng Nuo Biotec 688117.SSChina$433M-48%+51%27%3.4×-0.2%+14.5%
Zhejiang Huakang Pharmaceutical 605077.SSChina$433M-47%+35%4%1.1×n/an/a
Kexing Biopharm 688136.SSChina$433M-42%-14%-12%2.9×n/an/a
Elixiron Immunotherapeutics (Cayman) 7871.TWOTaiwan$412M+64%+6,162%-194%119.7×n/an/a
Jiangsu Sihuan Bioengineering 000518.SZChina$437M-8%-17%-28%10.6×n/an/a
PKU Healthcare 000788.SZChina$437M-12%-49%5%2.1×-5.6%-5.6%
Harbin Medisan Pharmaceutical 002900.SZChina$437M-16%-5%-29%4.2×n/an/a
Rezolute RZLTUnited States$411M+32%n/an/an/an/an/a
CytomX Therapeutics CTMXUnited States$410M-49%-88%-676%4.7×n/an/a

Questions

Which companies are Hyundai Bioscience's closest peers?
The cockpit's peer set: Synmosa Biopharma (4114.TWO), Beijing Foyou Pharma (601089.SS), JW Pharmaceutical (001060.KS), Ovid Therapeutics (OVID), Zota Health Care (ZOTA.NS), Tevogen (TVGN), Shanghai Shenqi Pharmaceutical Investment Management (600613.SS), Shaanxi Kanghui Pharmaceutical Co (603139.SS).
Is Hyundai Bioscience expensive compared with its peers?
On ev / sales it trades at 164.0× against a peer median of 3.0×, 2nd most expensive of 19 in its peer set.
How has Hyundai Bioscience stock performed?
Over six months to 18 Nov 2026 the shares returned -50.2% against -20.8% for the median peer; over one year +16.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.